Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride replenishes potassium stores. Dextrose provides caloric support via glucose metabolism. Sodium chloride maintains osmotic balance and fluid volume.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion only; typical adult dose is 1 L at a rate of 100-200 mL/hour, delivering 0.22% KCl (2.2 g KCl = 29.9 mEq K+), 5% dextrose, and 0.11% NaCl (1.1 g NaCl = 18.8 mEq Na+, 18.8 mEq Cl-). Dose depends on potassium deficit and renal function.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium does not have a defined terminal half-life in the traditional sense, as it is tightly regulated. The elimination half-life of potassium ions from the plasma is approximately 1-1.5 hours for acute distribution, but the overall body turnover is much slower. In clinical context, after IV infusion, plasma concentration declines rapidly due to cellular uptake and renal excretion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted renally (about 90%) with the remainder eliminated via feces. In this formulation, the dextrose and sodium chloride are also excreted renally, with dextrose being fully reabsorbed when normoglycemic. Excretion data for potassium: renal ~90%, fecal ~10%.
Category C
Category A/B
Electrolyte
Electrolyte